ArticleBMC medicine2026
A lesion-derived brain network of somatic symptoms for transdiagnostic individual application.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundSomatic symptoms is an umbrella term that describes distressing somatic complaints occurring across a wide spectrum of diseases. However, their underlying neural mechanisms remain poorly understood. Elucidating their mechanisms could therefore benefit patients with diverse conditions.
methodsUsing a recently validated lesion network mapping method and a large-scale healthy connectome database (n = 652, recruited in Anhui Province, China), we identified a somatic network from brain lesions causing somatic symptoms. The lesion-derived network was validated using independent multimodal neuroimaging signatures of somatic symptoms and interoceptive processing. It was further characterized by transcriptomic, neurochemical, and cognitive meta-analytic mapping. We further assessed the therapeutic potential of the somatic network by quantifying its spatial convergence with empirically validated neuromodulation targets. Finally, to determine whether the group-level network can predict personalized symptom severity across diagnoses, we built a normative model of gray matter volume using Gaussian process regression based on 1,342 healthy controls from Anhui. This model was then used to generate personalized atrophy maps in 399 local somatic patients with anxiety, depression, schizophrenia and bipolar disorder. We then assessed whether individual atrophy volume within the somatic network was associated with somatic symptom severity.
resultsWe found that 21 heterogeneous lesions associated somatic symptoms occurred in many different brain locations but were characterized by a common brain network, with the hub region of the right insula and putamen. The somatic network demonstrated strong spatial alignment with multimodal somatic imaging abnormalities from 66 independent studies and interoceptive processing circuits from 69 task-fMRI studies. 11 effective brain stimulation targets were colocalization with the somatic network. In individual transdiagnostic patients, greater atrophy volume within the somatic network was significantly correlated with somatic symptom severity (r = 0.182, p = 0.004), but not with anxiety or depression symptoms.
conclusionsThese convergent findings establish a unified somatic network framework, advancing both mechanistic understanding and precision medicine applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.